News ISR Immune System Regulation Holding AB (publ)

Equities

ISR

SE0008212195

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immune System Regulation AB Announces Sars-Cov-2 Dry Powder Nasal - Vaccine Booster Candidate, Isr52, Demonstrates Superior Immune Response, in Mouse Model Challenge Studies Compared to Subcutaneous injection of this vaccine	28/08/23	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Half Year Ended June 30, 2022	31/08/22	CI
ISR Receives Approval To Conduct Clinical Trial In Bangladesh	01/07/22	MT
SARS-CoV-2 vaccine study approved by Bangladesh BMRC	01/07/22	AQ
ISR’s Immune System Regulation Holding AB Announces Sars-Cov-2 Vaccine Study Approved by Bangladesh Bmrc	01/07/22	CI
ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.	28/06/22	AQ
ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to Scale-Up Its Spray-Dried Nasal Vaccine, Powder Formulation for Phase III	28/06/22	CI
Delegation from Bangladesh visits ISR for study preparation	20/06/22	AQ
ISR Immune System Regulation : Holding Annual Report and Consolidated Accounts 2021 (eng) (PDF)	14/06/22	PU
Redeye Initiates Coverage of ISR Holding	05/05/22	AQ
ISR - Immune System Regulation Holding AB (publ.) 2[nd] half of 2021, including year-end report is now published on the website: www.israb.se	23/02/22	PU
ISR Immune System Regulation Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	23/02/22	CI
ISR Immune System Regulation Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021	23/02/22	CI
Iconovo : ISR to Test Inhalable, Nasal COVID-19 Vaccines in Bangladesh	27/08/21	MT
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Half Year Ended June 30, 2021	25/08/21	CI
Iconovo : receives an order for additional work from ISR for development of a nasal COVID-19 vaccine	12/07/21	AQ
BioStock: Iconovo and ISR develop new covid-19 inhalation vaccine	01/04/21	AQ
Iconovo : signs agreement with ISR for the development of inhaled covid-19 vaccine	31/03/21	AQ
Isr Immune System Regulation Holding AB Publ Reports Earnings Results for the Full Year Ended December 31, 2020	24/02/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ISR Immune System Regulation Holding AB (publ)

Equities

ISR

SE0008212195

Summary

Filters